Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia

Frontiers in Pediatrics

Volumn 3, Issue , 2015, Pages

  Shalabi, Haneen ^a   Angiolillo, Anne ^a   Fry, Terry J ^b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

adoptive; chimeric antigen receptor; chimeric antigen receptor safety; immunotherapy; pediatric acute leukemia; relapsed leukemia

Indexed keywords

EID: 84995761258     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2015.00080     Document Type: Review

References (109)

1. Howlader N Noone A Krapcho M Garshell J Miller D Altekruse S et al. SEER Cancer Statistics Review, 1975–2011. Bethesda, MD: National Cancer Institute (2014).
2. Hunger SP Lu X Devidas M Camitta BM Gaynon PS Winick NJ et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children’s Oncology Group. J Clin Oncol (2012) 30:1663–9.10.1200/JCO.2011.37.801822412151
3. Rabin Z-MP. Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Children’s Oncology Group Protocol: AALL08B1 (2015).
4. Schultz KR Pullen DJ Sather HN Shuster JJ Devidas M Borowitz MJ et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood (2007) 109:926–35.10.1182/blood-2006-01-02472917003380
5. Carroll W Hunger S Borowitz M Bhojwani D Willman C Devidas M et al. Risk-adapted therapy for children with acute lymphoblastic leukemia (ALL): the Children’s Oncology Group (COG) approach. Ann Hematol (2008) 87:S42–4.10.1007/s00277-008-0443-6
6. Henze G v Stackelberg A Eckert C. ALL-REZ BFM – the consecutive trials for children with relapsed acute lymphoblastic leukemia. Klin Padiatr (2013) 225(Suppl 1):S73–8.10.1055/s-0033-133796723700062
7. Tallen G Ratei R Mann G Kaspers G Niggli F Karachunsky A et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol (2010) 28:2339–47.10.1200/JCO.2009.25.198320385996
8. Henze G Fengler R Hartmann R Kornhuber B Janka-Schaub G Niethammer D et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood (1991) 78:1166–72.1878583
9. Gaynon PS Harris RE Altman AJ Bostrom BC Breneman JC Hawks R et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children’s Oncology Group study CCG-1941. J Clin Oncol (2006) 24:3150–6.10.1200/JCO.2005.04.585616717292
10. Bhojwani D Howard SC Pui C-H. High-risk childhood acute lymphoblastic leukemia. Clin Lymphoma Myeloma (2009) 9:S222.10.3816/CLM.2009.s.01619778845
11. Ritchey AK Pollock BH Lauer SJ Andejeski Y Barredo J Buchanan GR. Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol (1999) 17:3745–52.10577846
12. Barredo JC Devidas M Lauer SJ Billett A Marymont M Pullen J et al. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a Pediatric Oncology Group study. J Clin Oncol (2006) 24:3142–9.10.1200/JCO.2005.03.337316809737
13. Raetz EA Borowitz MJ Devidas M Linda SB Hunger SP Winick NJ et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study [corrected]. J Clin Oncol (2008) 26:3971–8.10.1200/JCO.2008.16.141418711187
14. Freyer DR Devidas M La M Carroll WL Gaynon PS Hunger SP et al. Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children’s Oncology Group. Blood (2011) 117:3010–5.10.1182/blood-2010-07-29467821193696
15. Rivera GK Zhou Y Hancock ML Gajjar A Rubnitz J Ribeiro RC et al. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer (2005) 103:368–76.10.1002/cncr.2074315599932
16. Schultz KR Carroll A Heerema NA Bowman WP Aledo A Slayton WB et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031. Leukemia (2014) 28:1467–71.10.1038/leu.2014.3024441288
17. Roberts KG Li Y Payne-Turner D Harvey RC Yang YL Pei D et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 371:1005–15.10.1056/NEJMoa140308825207766
18. Den Boer ML van Slegtenhorst M De Menezes RX Cheok MH Buijs-Gladdines JG Peters ST et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 10:125–34.10.1016/S1470-2045(08)70339-519138562
19. Raimondi SC Zhou Y Mathew S Shurtleff SA Sandlund JT Rivera GK et al. Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer (2003) 98:2715–22.10.1002/cncr.1184114669294
20. Nachman JB Heerema NA Sather H Camitta B Forestier E Harrison CJ et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood (2007) 110:1112–5.10.1182/blood-2006-07-03829917473063
21. Mehta PA Zhang MJ Eapen M He W Seber A Gibson B et al. Transplantation outcomes for children with hypodiploid acute lymphoblastic leukemia. Biology of blood and marrow transplantation. J Am Society Blood Marrow Transplant (2015) 21:1273–7.10.1016/j.bbmt.2015.04.00825865650
22. Coustan-Smith E Sancho J Hancock ML Boyett JM Behm FG Raimondi SC et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood (2000) 96:2691–6.11023499
23. Borowitz MJ Devidas M Hunger SP Bowman WP Carroll AJ Carroll WL et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood (2008) 111:5477–85.10.1182/blood-2008-01-13283718388178
24. Borowitz MJ Wood BL Devidas M Loh ML Raetz EA Salzer WL et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood (2015) 126:964–71.10.1182/blood-2015-03-63368526124497
25. Sramkova L Muzikova K Fronkova E Krejci O Sedlacek P Formankova R et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer (2007) 48:93–100.10.1002/pbc.2079416521130
26. Leung W Pui CH Coustan-Smith E Yang J Pei D Gan K et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood (2012) 120:468–72.10.1182/blood-2012-02-40981322517895
27. Pulsipher MA Langholz B Wall DA Schultz KR Bunin N Carroll WL et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood (2014) 123:2017–25.10.1182/blood-2013-10-53429724497539
28. Pulsipher MA Carlson C Langholz B Wall DA Schultz KR Bunin N et al. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood (2015) 125:3501–8.10.1182/blood-2014-12-61575725862561
29. Leung W Campana D Yang J Pei D Coustan-Smith E Gan K et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood (2011) 118:223–30.10.1182/blood-2011-01-33307021613256
30. Druley TE Hayashi R Mansur DB Zhang QJ Barnes Y Trinkaus K et al. Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI. Bone Marrow Transplant (2009) 43:307–14.10.1038/bmt.2008.32719011666
31. Shi-Xia X Xian-Hua T Hai-Qin X Bo F Xiang-Feng T. Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis. Leuk Lymphoma (2010) 51:50–60.10.3109/1042819090341913020055658
32. Oliansky DM Camitta B Gaynon P Nieder ML Parsons SK Pulsipher MA et al. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant (2012) 18:505–22.10.1016/j.bbmt.2011.12.58522209888
33. Balduzzi A Valsecchi MG Uderzo C De Lorenzo P Klingebiel T Peters C et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet (2005) 366:635–42.10.1016/S0140-6736(05)66998-X16112299
34. Conter V Valsecchi MG Parasole R Putti MC Locatelli F Barisone E et al. Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood (2014) 123:1470–8.10.1182/blood-2013-10-53259824415536
35. Pinkel D. ‘Allogeneic marrow transplantation in children with acute leukemia: a practice whose time has gone’: twenty years later. Leukemia (2009) 23:2189–96.10.1038/leu.2009.132
36. Pulsipher MA Hunger SP Gamis AS Wall DA Grupp SA. Allogeneic marrow transplantation in children with acute leukemia: careful comparison with chemotherapy alternatives required. Leukemia (2010) 24:1212–6.10.1038/leu.2010.72
37. Kotecha RS Gottardo NG Kees UR Cole CH. The evolution of clinical trials for infant acute lymphoblastic leukemia. Blood Cancer J (2014) 4:e200.10.1038/bcj.2014.1724727996
38. Hilden JM Dinndorf PA Meerbaum SO Sather H Villaluna D Heerema NA et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children’s Oncology Group. Blood (2006) 108:441–51.10.1182/blood-2005-07-301116556894
39. Reaman GH Sposto R Sensel MG Lange BJ Feusner JH Heerema NA et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children’s Cancer Group. J Clin Oncol (1999) 17:445–55.10080584
40. Pieters R Schrappe M De Lorenzo P Hann I De Rossi G Felice M et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet (2007) 370:240–50.10.1016/S0140-6736(07)61126-X17658395
41. Isoyama K Eguchi M Hibi S Kinukawa N Ohkawa H Kawasaki H et al. Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96). Br J Haematol (2002) 118:999–1010.10.1046/j.1365-2141.2002.03754.x12199778
42. Tomizawa D Koh K Hirayama M Miyamura T Hatanaka M Saikawa Y et al. Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: a report from the Japan Infant Leukemia Study Group. Pediatr Blood Cancer (2009) 52:808–13.10.1002/pbc.2197519229974
43. Nagayama J Tomizawa D Koh K Nagatoshi Y Hotta N Kishimoto T et al. Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group. Blood (2006) 107:4663–5.10.1182/blood-2005-11-472816478880
44. Tomizawa D Koh K Sato T Kinukawa N Morimoto A Isoyama K et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia (2007) 21:2258–63.10.1038/sj.leu.240490317690691
45. Pui CH Gaynon PS Boyett JM Chessells JM Baruchel A Kamps W et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet (2002) 359:1909–15.10.1016/S0140-6736(02)08782-212057554
46. Kang H Wilson CS Harvey RC Chen IM Murphy MH Atlas SR et al. Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood (2012) 119:1872–81.10.1182/blood-2011-10-38286122210879
47. Hilden BP et al. A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy ± FLT3 Inhibition Children’s Oncology Group: AALL0631. (2013).
48. Brown P. Treatment of infant leukemias: challenge and promise. Hematology Am Soc Hematol Educ Program (2013) 2013:596–600.10.1182/asheducation-2013.1.59624319237
49. Seibel NL Steinherz PG Sather HN Nachman JB Delaat C Ettinger LJ et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood (2008) 111:2548–55.10.1182/blood-2007-02-07034218039957
50. Einsiedel HG von Stackelberg A Hartmann R Fengler R Schrappe M Janka-Schaub G et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol (2005) 23:7942–50.10.1200/JCO.2005.01.103116258094
51. Coustan-Smith E Mullighan CG Onciu M Behm FG Raimondi SC Pei D et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 10:147–56.10.1016/S1470-2045(08)70314-019147408
52. Wood BL Winter SS Dunsmore KP Devidas M Chen S Asselin B et al. T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434, 56th ASH Annual Meeting and Exposition. (2014).
53. Dunsmore KP et al. T-CELL PILOT PROTOCOL The Use of Modified BFM ± Compound 506U78 (Nelarabine) (NSC# 686673, IND #52611) in an Intensive Chemotherapy Regimen for the Treatment of T-Cell Leukemia Children’s Oncology Group: AALL00P2. (2005).
54. Berg SL Blaney SM Devidas M Lampkin TA Murgo A Bernstein M et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J Clin Oncol (2005) 23:3376–82.10.1200/JCO.2005.03.42615908649
55. Kaspers GJ Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia (2005) 19:2025–9.10.1038/sj.leu.2403958
56. Wheatley K Burnett AK Goldstone AH Gray RG Hann IM Harrison CJ et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom medical research council’s adult and childhood leukaemia working parties. Br J Haematol (1999) 107:69–79.10.1046/j.1365-2141.1999.01684.x10520026
57. Kiyoi H Naoe T Nakano Y Yokota S Minami S Miyawaki S et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood (1999) 93:3074–80.10216104
58. Annesley CE Brown P. The biology and targeting of FLT3 in pediatric leukemia. Front Oncol (2014) 4:263.10.3389/fonc.2014.0026325295230
59. Kiyoi H Towatari M Yokota S Hamaguchi M Ohno R Saito H et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia (1998) 12:1333–7.10.1038/sj.leu.24011309737679
60. Smith FO Alonzo TA Gerbing RB Woods WG Arceci RJ Children’s Cancer G. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children’s Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia (2005) 19:2054–62.10.1038/sj.leu.240392516136168
61. Lange BJ Smith FO Feusner J Barnard DR Dinndorf P Feig S et al. Outcomes in CCG-2961, a children’s oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. Blood (2008) 111:1044–53.10.1182/blood-2007-04-08429318000167
62. Aplenc RSL Meshinchi S et al. A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD Children’s Oncology Group: AAML1031. (2014).
63. Schreiber RD Old LJ Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science (2011) 331:1565–70.10.1126/science.120348621436444
64. Marr LA Gilham DE Campbell JD Fraser AR. Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies. Clin Exp Immunol (2012) 167:216–25.10.1111/j.1365-2249.2011.04517.x22235997
65. Chmielewski M Hombach AA Abken H. Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells. Front Immunol (2013) 4:371.10.3389/fimmu.2013.0037124273543
66. Gross G Waks T Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA (1989) 86:10024–8.10.1073/pnas.86.24.100242513569
67. Fry TJ Mackall CL. T-cell adoptive immunotherapy for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program (2013) 2013:348–53.10.1182/asheducation-2013.1.34824319203
68. Kershaw MH Westwood JA Slaney CY Darcy PK. Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology (2014) 3:e16.10.1038/cti.2014.725505964
69. Savoldo B Ramos CA Liu E Mims MP Keating MJ Carrum G et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 121:1822–6.10.1172/JCI4611021540550
70. Han EQ Li XL Wang CR Li TF Han SY. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol (2013) 6:47.10.1186/1756-8722-6-4723829929
71. Vedi A Ziegler DS. Antibody therapy for pediatric leukemia. Front Oncol (2014) 4:82.10.3389/fonc.2014.0008224795859
72. Topp MS Kufer P Gokbuget N Goebeler M Klinger M Neumann S et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol (2011) 29:2493–8.10.1200/JCO.2010.32.727021576633
73. Gore L Zugmaier G Handgretinger R Locatelli F Trippett TM Rheingold SR et al. Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic (ALL). J Clin Oncol (2013) 31.
74. Maude SL Frey N Shaw PA Aplenc R Barrett DM Bunin NJ et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 371:1507–17.10.1056/NEJMoa140722225317870
75. Lee DW Kochenderfer JN Stetler-Stevenson M Cui YK Delbrook C Feldman SA et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (2015) 385:517–28.10.1016/S0140-6736(14)61403-325319501
76. Topp MS Gokbuget N Zugmaier G Degenhard E Goebeler ME Klinger M et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood (2012) 120:5185–7.10.1182/blood-2012-07-44103023024237
77. Shah NN Bhojwani D Silverman LB Whitlock JA Richards K Stetler-Stevenson M et al. A novel anti-Cd22 immunotoxin, moxetumomab pasudotox (Ha22, Cat-8015): activity in pediatric patients with relapsed acute lymphoblastic leukemia (All) after allogeneic hematopoietic stem cell transplantation (Sct). Biol Blood Marrow Transplant (2012) 18:S234–234.10.1016/j.bbmt.2011.12.091
78. Mussai F Campana D Bhojwani D Stetler-Stevenson M Steinberg SM Wayne AS et al. Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol (2010) 150:352–8.10.1111/j.1365-2141.2010.08251.x20528877
79. Kantarjian H Thomas D Jorgensen J Kebriaei P Jabbour E Rytting M et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer (2013) 119:2728–36.10.1002/cncr.2813623633004
80. Haso W Lee DW Shah NN Stetler-Stevenson M Yuan CM Pastan IH et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood (2013) 121:1165–74.10.1182/blood-2012-06-43800223243285
81. Qin H Cho M Haso W Zhang L Tasian SK Oo HZ et al. Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood (2015) 126:629–39.10.1182/blood-2014-11-61290326041741
82. Orentas RJ Yang JJ Wen X Wei JS Mackall CL Khan J. Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. Front Oncol (2012) 2:194.10.3389/fonc.2012.0019423251904
83. Orentas RJ Nordlund J He J Sindiri S Mackall C Fry TJ et al. Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison. Front Oncol (2014) 4:134.10.3389/fonc.2014.0013424959420
84. Ramos CA Savoldo B Liu EL Gee AP Mei ZY Grilley B et al. Clinical responses in patients infused with T lymphocytes redirected to target kappa-light immunoglobulin chain. Mol Ther (2013) 21:S114–114.10.1016/j.bbmt.2013.12.009
85. Seon BK Negoro S Barcos MP. Monoclonal antibody that defines a unique human T-cell leukemia antigen. Proc Natl Acad Sci USA (1983) 80:845–9.10.1073/pnas.80.3.8456600841
86. Hara H Seon BK. Complete suppression of in vivo growth of human leukemia cells by specific immunotoxins: nude mouse models. Proc Natl Acad Sci USA (1987) 84:3390–4.10.1073/pnas.84.10.33903494997
87. Maude SL Dolai S Delgado-Martin C Vincent T Robbins A Selvanathan A et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood (2015) 125:1759–67.10.1182/blood-2014-06-58048025645356
88. Mamonkin M Rouce RH Tashiro H Brenner MK. A T cell-directed chimeric antigen receptor for the selective treatment of T cell malignancies. Blood (2015) 126:983–92.10.1182/blood-2015-02-62952726056165
89. Gamis AS Alonzo TA Meshinchi S Sung L Gerbing RB Raimondi SC et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol (2014) 32:3021–32.10.1200/JCO.2014.55.362825092781
90. Kenderian SS Ruella M Shestova O Klichinsky M Aikawa V Morrissette JJ et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia (2015) 29:1637–47.10.1038/leu.2015.5225721896
91. O’Hear C Heiber JF Schubert I Fey G Geiger TL. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica (2015) 100:336–44.10.3324/haematol.2014.11274825480499
92. Pizzitola I Anjos-Afonso F Rouault-Pierre K Lassailly F Tettamanti S Spinelli O et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia (2014) 28:1596–605.10.1038/leu.2014.6224504024
93. Tettamanti S Marin V Pizzitola I Magnani CF Giordano Attianese GM Cribioli E et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol (2013) 161:389–401.10.1111/bjh.1228223432359
94. Mardiros A Dos Santos C McDonald T Brown CE Wang X Budde LE et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood (2013) 122:3138–48.10.1182/blood-2012-12-47405624030378
95. Gill S Tasian SK Ruella M Shestova O Li Y Porter DL et al. Efficacy against human acute myeloid leukemia and myeloablation of normal hematopoiesis in a mouse model using chimeric antigen receptor-modified T cells. Blood (2014) 123:2343–54.10.1182/blood-2013-09-529537
96. Ritchie DS Neeson PJ Khot A Peinert S Tai T Tainton K et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther (2013) 21:2122–9.10.1038/mt.2013.15423831595
97. Lynn RC Poussin M Kalota A Feng Y Low PS Dimitrov DS et al. Targeting of folate receptor beta on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood (2015) 125:3466–76.10.1182/blood-2014-11-61272125887778
98. Grada Z Hegde M Byrd T Shaffer DR Ghazi A Brawley VS et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids (2013) 2:e105.10.1038/mtna.2013.3223839099
99. Kloss CC Condomines M Cartellieri M Bachmann M Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol (2013) 31:71–5.10.1038/nbt.245923242161
100. Lanitis E Poussin M Klattenhoff AW Song D Sandaltzopoulos R June CH et al. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res (2013) 1:43–53.10.1158/2326-6066.CIR-13-000824409448
101. Pui CH Behm FG Singh B Rivera GK Schell MJ Roberts WM et al. Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood (1990) 75:198–202.2294988
102. Wiersma SR Ortega J Sobel E Weinberg KI. Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med (1991) 324:800–8.10.1056/NEJM1991032132412041997852
103. Putti MC Rondelli R Cocito MG Arico M Sainati L Conter V et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood (1998) 92:795–801.9680347
104. Suggs JL Cruse JM Lewis RE. Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias. Exp Mol Pathol (2007) 83:471–3.10.1016/j.yexmp.2007.08.01217963747
105. Bhushan B Chauhan PS Saluja S Verma S Mishra AK Siddiqui S et al. Aberrant phenotypes in childhood and adult acute leukemia and its association with adverse prognostic factors and clinical outcome. Clin Exp Med (2010) 10:33–40.10.1007/s10238-009-0067-819779962
106. Morgan RA Yang JC Kitano M Dudley ME Laurencot CM Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 18:843–51.10.1038/mt.2010.2420179677
107. Di Stasi A Tey SK Dotti G Fujita Y Kennedy-Nasser A Martinez C et al. Inducible apoptosis as a safety switch for adoptive cell therapy. New Engl J Med (2011) 365:1673–83.10.1056/NEJMoa110615222047558
108. Zhao Y Moon E Carpenito C Paulos CM Liu X Brennan AL et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res (2010) 70:9053–61.10.1158/0008-5472.CAN-10-288020926399
109. Wang X Chang WC Wong CW Colcher D Sherman M Ostberg JR et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood (2011) 118:1255–63.10.1182/blood-2011-02-33736021653320